... wide range of next-generation features into a sma... for flexible laboratory solutions. It puts every ...lution, dispensing, and integrations into a singl... as it is efficient and economical. The Biomek NX ...
BD Falcon 96-well Flat-bottom ELISA Plates from BD Biosciences - Discovery Labware
Detergent-OUT Micro Kit from CHEMICON
Detergent-OUT (SDS) from CHEMICON
Biology Products:(Date:11/24/2009)...y endpoint has been met for patients with advanced... QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEt... "Company"), a global biopharmaceutical company fo...ounced positive efficacy data from a Phase 2 study...ZS-108 (formerly AN-152), in patients with advance...
(Date:11/24/2009)... 24 Shire plc (LSE: SHP,...eutical company, today,announced that it has submi...laglucerase alfa, the company,s enzyme replacement...1 Gaucher disease. This is the third marketing,app...itted, with previous,submissions in the United Sta...
(Date:11/24/2009)...., Nov. 24 Genomic Healt...y Scott, Genomic Health,s Executive Chairman, will...are Conference in New York City on Tuesday, Decemb...live and subsequently archived webcast of the pres...Genomic Health,s website at http://investor.genom...
(Date:11/24/2009)... Connects Customers with Partners Validated to Pro...k Products , Ottawa, ON (...ng provider of products for biological sample coll...nced its new global partner program. The program o...artner community and is designed to help partners ...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3